Trastuzumab (Herceptin®, Genentech), a humanized monoclonal antibody targeting HER2, has been approved for the treatment of HER2 positive early-stage breast cancer, metastatic breast cancer and metastatic cancer of the stomach or gastroesophageal junction [6]. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm.